OA03.04 Tislelizumab Plus Chemotherapy Vs Chemotherapy Alone As First-line Treatment for Advanced Squamous Non-Small Cell Lung Cancer

J. Wang,S. Lu,C. Hu,Y. Sun,K. Yang,M. Chen,J. Zhao,G. Yu,X. Zhou,G. Feng,Y. Pan,Y. Yu,J. Zhang,L. Liang,X. Lin,J. Cui

DOI: https://doi.org/10.1016/j.jtho.2020.10.024

IF: 20.121

2021-01-01

Journal of Thoracic Oncology

Abstract:PD-1/L1 inhibitors have provided new treatment approaches for patients with advanced NSCLC; however, resistance or low PD-L1 expression may limit clinical benefit. Tislelizumab, an anti-PD-1 monoclonal antibody, was engineered to minimize binding to FcγR on macrophages to abrogate antibody-dependent phagocytosis, a mechanism of T-cell clearance and potential resistance to anti-PD-1 therapy. Tislelizumab, alone and with chemotherapy, demonstrated antitumor activity and was generally well tolerated in patients with advanced NSCLC, irrespective of PD-L1 expression. This open-label phase 3 study (NCT03594747) evaluated the efficacy and safety/tolerability of tislelizumab plus chemotherapy as first-line treatment in Chinese patients with histologically confirmed stage IIIB/IV squamous NSCLC. Patients (randomized 1:1:1) received IV Q3W: tislelizumab (200 mg, D1) plus paclitaxel (175 mg/m2, D1) and arboplatin (AUC 5, D1) (Arm A); tislelizumab plus nab-paclitaxel (100 mg/m2; D1, 8, and 15) and carboplatin (AUC 5, D1) (Arm B); or paclitaxel (175 mg/m2, D1) and carboplatin (AUC 5, D1) (Arm C). Patients were stratified by disease stage (IIIB vs IV) and tumor cell PD-L1 expression (<1% vs 1-49% vs ≥50%) as assessed using the VENTANA PD-L1 (SP263) Assay. Chemotherapy was administered for 4-6 cycles at investigator’s discretion; crossover to tislelizumab monotherapy was allowed for patients in Arm C. The primary endpoint was PFS by Independent Review Committee per RECIST v1.1; secondary endpoints included ORR, DoR per RECIST v1.1, OS, and safety/tolerability. Across the 360 patients, PFS was significantly improved and higher ORR/DoR was observed with combination treatment (A and B) versus chemotherapy (C); there was no apparent relationship between PD-L1 expression and PFS or ORR (Table). Across all arms, median OS was not reached. Median number of treatment cycles was comparable across all arms and discontinuation of any treatment due to AEs was reported in 12.5%, 29.7%, and 15.4% of patients in Arms A, B, and C, respectively. The most common grade ≥3 AE was decreased neutrophil count, in line with known hematological toxicity of chemotherapy. Treatment-related AEs leading to death occurred in six patients (n=1 [A]; n=2 [B]; n=3 [C]); none were solely attributed to tislelizumab. First-line tislelizumab plus paclitaxel/carboplatin or nab-paclitaxel/carboplatin significantly improved PFS for patients with squamous NSCLC and demonstrated higher ORR than chemotherapy alone, irrespective of PD-L1 expression. The safety profile was comparable with those of tislelizumab, chemotherapy, and underlying NSCLC; no new safety signals were identified with the addition of tislelizumab to chemotherapy.